Importance: Data are lacking whether patients with hypertension who are taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) have increased severity or risk of mortality during hospitalization for coronavirus disease 2019 (COVID-19).
Objective: To investigate the association between ACEIs/ARBs and severity of illness and mortality in patients with hypertension hospitalized for COVID-19 infection.
Design, setting, and participants: Retrospective, single-center case series of the 1178 hospitalized patients with COVID-19 infections at the Central Hospital of Wuhan, China, from January 15 to March 15, 2020.
Main outcomes and measures: COVID-19 was confirmed by real-time reverse transcription-polymerase chain reaction and epidemiologic, clinical, radiologic, laboratory, and drug therapy data were analyzed in all patients. The percentage of patients with hypertension taking ACEIs/ARBs was compared between those with severe vs nonsevere illness and between survivors vs nonsurvivors.
Results: Of the 1178 patients with COVID-19, the median age was 55.5 years (interquartile range, 38-67 years) and 545 (46.3%) were men. The overall in-hospital mortality was 11.0%. There were 362 patients with hypertension (30.7% of the total group; median age, 66.0 years [interquartile range, 59-73 years]; 189 [52.2%] were men), of whom 115 (31.8%) were taking ACEI/ARBs. The in-hospital mortality in the patients with hypertension was 21.3%. The percentage of patients with hypertension taking ACEIs/ARBs did not differ between those with severe and nonsevere infections (32.9% vs 30.7%; P = .65) nor did it differ between nonsurvivors and survivors (27.3% vs 33.0%; P = .34). Similar findings were observed when data were analyzed for patients taking ACEIs and those taking ARBs.
Conclusions and relevance: This study provides clinical data on the association between ACEIs/ARBs and outcomes in patients with hypertension hospitalized with COVID-19 infections, suggesting that ACEIs/ARBs are not associated with the severity or mortality of COVID-19 in such patients. These data support current guidelines and societal recommendations for treating hypertension during the COVID-19 pandemic.
Conflict of interest statement
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).JAMA Cardiol. 2020 May 5:e201855. doi: 10.1001/jamacardio.2020.1855. Online ahead of print. JAMA Cardiol. 2020. PMID: 32369097 Free PMC article.
The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension.Ann Transl Med. 2020 Apr;8(7):430. doi: 10.21037/atm.2020.03.229. Ann Transl Med. 2020. PMID: 32395474 Free PMC article.
Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study.Hypertension. 2020 Apr 29. doi: 10.1161/HYPERTENSIONAHA.120.15143. Online ahead of print. Hypertension. 2020. PMID: 32348166
Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.Mayo Clin Proc. 2020 Apr 4;95(6):1222-30. doi: 10.1016/j.mayocp.2020.03.026. Online ahead of print. Mayo Clin Proc. 2020. PMID: 32376099 Free PMC article. Review.
Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.J Manag Care Pharm. 2011 Oct;17(8 Suppl):S1-14. doi: 10.18553/jmcp.2011.17.s8.1. J Manag Care Pharm. 2011. PMID: 22088101 Review.
Cited by 6 articles
Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators.Acta Cardiol Sin. 2020 May;36(3):179-182. doi: 10.6515/ACS.202005_36(3).20200430A. Acta Cardiol Sin. 2020. PMID: 32425432 Free PMC article. No abstract available.
Antagonizing the renin-angiotensin-aldosterone system in the era of COVID-19.Intern Emerg Med. 2020 May 18:1-3. doi: 10.1007/s11739-020-02365-5. Online ahead of print. Intern Emerg Med. 2020. PMID: 32424634 Free PMC article. No abstract available.
[Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.].MMW Fortschr Med. 2020 May;162(9):67-69. doi: 10.1007/s15006-020-0483-y. MMW Fortschr Med. 2020. PMID: 32405833 Free PMC article. Review. German.
COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?Pharmacol Res. 2020 May 13;158:104906. doi: 10.1016/j.phrs.2020.104906. Online ahead of print. Pharmacol Res. 2020. PMID: 32405229 Free PMC article. Review.
COVID-19, Angiotensin Receptor Blockers, and the Brain.Cell Mol Neurobiol. 2020 Jul;40(5):667-674. doi: 10.1007/s10571-020-00861-y. Epub 2020 May 8. Cell Mol Neurobiol. 2020. PMID: 32385549 Free PMC article. No abstract available.